Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 550 of 1475 entries
View as:

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01621490 Org: User:
Start: 09/27/12 End: 10/25/18 Due: 10/25/19

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00094653 Org: User:
Start: 09/30/04 End: 10/31/09 Due: 10/31/10

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase: N/A Priority: Normal
NCT ID: NCT03519256 Org: User:
Start: 08/02/18 End: 08/24/22 Due: 08/24/23

An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection

Phase: N/A Priority: Normal
NCT ID: NCT01037062 Org: User:
Start: 12/31/03 End: 12/31/06 Due: 12/31/07

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03599622 Org: User:
Start: 07/16/18 End: 10/23/23 Due: 10/23/24

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Phase: N/A Priority: Normal
NCT ID: NCT02654132 Org: User:
Start: 03/18/16 End: 10/21/21 Due: 10/21/22

BMS-986012 in Relapsed/Refractory SCLC

Phase: N/A Priority: Normal
NCT ID: NCT02247349 Org: User:
Start: 11/14/14 End: 12/22/22 Due: 12/22/23

Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06566768 Org: User:
Start: 10/07/24 End: 06/12/25 Due: 06/12/26

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02913313 Org: User:
Start: 11/30/16 End: 01/25/24 Due: 01/25/25

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00289640 Org: User:
Start: 04/30/06 End: 07/31/07 Due: 07/31/08

Effect of Diltiazem on Pharmacokinetics of BMS-914392

Phase: N/A Priority: Normal
NCT ID: NCT01211808 Org: User:
Start: 09/30/10 End: 10/31/10 Due: 10/31/11

Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00035152 Org: User:
Start: 06/30/00 End: 12/31/04 Due: 12/31/05

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Phase: N/A Priority: Normal
NCT ID: NCT02156804 Org: User:
Start: 10/07/14 End: 01/18/19 Due: 01/18/20

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT03419910 Org: User:
Start: 03/05/18 End: 05/04/18 Due: 05/04/19

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06419634 Org: User:
Start: 05/29/24 End: 09/16/30 Due: 09/16/31

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT00028067 Org: User:
Start: 08/31/01 End: 04/30/02 Due: 04/30/03

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT04016753 Org: User:
Start: 08/05/19 End: 02/21/20 Due: 02/21/21

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

Phase: N/A Priority: Normal
NCT ID: NCT00605384 Org: User:
Start: 08/31/08 End: 02/28/09 Due: 02/28/10

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02922452 Org: User:
Start: 09/30/16 End: 11/30/16 Due: 11/30/17

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00355238 Org: User:
Start: 12/31/06 End: 04/30/10 Due: 04/30/11

Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00051038 Org: User:
Start: 09/30/02 End: 10/31/05 Due: 10/31/06

Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00344552 Org: User:
Start: 06/30/06 End: 03/31/08 Due: 03/31/09

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02211469 Org: User:
Start: 08/31/14 End: 07/31/15 Due: 07/31/16

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

Phase: N/A Priority: Normal
NCT ID: NCT00095290 Org: User:
Start: 09/30/04 End: 11/30/05 Due: 11/30/06

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Phase: N/A Priority: Normal
NCT ID: NCT00546247 Org: User:
Start: 01/31/08 End: 03/31/10 Due: 03/31/11